Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Jump start for old antibiotics

Posted 26 February 2021 PM

A group of Australian researchers have received almost $3 million in funding from CARB-X, a global non-profit partnership funding the world's largest antibacterial development pipeline after their colleagues reached an important milestone.

The current project builds on the first Australian and first University CARB-X award to the Centre for Superbug Solutions in 2020 to develop the Octapeptin class as a stand-alone antibiotic treatment.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas